

**microRNA expression profiling on individual breast cancer patients identifies novel panel
of circulating microRNA for early detection**

Rimi Hamam¹, Arwa M Ali^{2,3}, Khalid A Alsaleh², Moustapha Kassem^{1,4}, Musaed Alfayez¹, Abdullah Aldahmash^{1,5}, Nehad M Alajez^{1*}


¹Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh 11461, Kingdom of Saudi Arabia

²Medical oncology unit, Department of Medicine, King Saud University, Riyadh 11461, Kingdom of Saudi Arabia


³Medical Oncology Department, South Egypt Cancer Institute, Assuit University, Egypt

⁴KMEB, Department of Endocrinology, University of Southern Denmark, Odense, Denmark


⁵Prince Naif Health Research Center, King Saud University, Riyadh 11461, Kingdom of Saudi Arabia



Supplementary figure 1. Isolation and concentration of circulating miRNAs from breast cancer patient' plasma. **(a)** Expression of miR-21 in representative breast cancer patient before (green) and after (red) speed-vacuum concentration and quantification using quantitative Real-Time PCR. **(b)** Data from (a) are presented as mean \pm SD, $n=3$.



Supplementary figure 2. Pie chart illustrating the distribution of the top 20 pathway designations for the predicted gene targets for 18 upregulated miRNAs in breast cancer circulation based on TargetScan database. The pie size corresponds to the number of matched entities.



Supplementary figure 3. Expression of hsv2-miR-H24 and hsv2-miR-H6 in the circulation of breast cancer patients (n=23) and normal controls (n=9) based on microRNA microarray expression. Data are presented as log₂ expression. Two tailed t-test was used to calculate significance.